HLA class II diversity in HIV-1 uninfected individuals from the placebo arm of the RV144 Thai vaccine efficacy trial

• Main Authors: K. M. Baldwin, P. K. Ehrenberg, A. Geretz, H. A. Prentice, S. Nitayaphan, S. Rerks-Ngarm, J. Kaewkungwal, P. Pitisuttithum, R. J. O'Connell, J. H. Kim, R. Thomas
• Other Authors: Walter Reed Army Institute of Research
• Format: Article
• Published: 2018
• Subjects: Biochemistry, Genetics and Molecular Biology; Immunology and Microbiology
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/35634
• Institution: Mahidol University

© 2015 John Wiley & Sons A/S. The RV144 HIV vaccine trial in Thailand elicited antibody responses to the envelope of HIV-1, which correlated significantly with the risk of HIV-1 acquisition. Human leukocyte antigen (HLA) class II molecules are essential in antigen presentation to CD4 T cells f...